

## Press Release

### **Lonza Issues CORE RONOA Guidance to 16% for 2016**

- **Capital Markets Day focuses on how Lonza is shaping its profile**
- **All other guidance remains unchanged**

**Basel, Switzerland, 20 May 2014** – Lonza is welcoming analysts and investors to the company's investor event at its Visp (CH) site from 20 to 21 May and offering them a close-up look at the company's strategic drivers of change. As part of the additional financial information and insights provided into the business, Lonza is announcing that the expected CORE RONOA for 2016 is 16%. All other guidance remains unchanged. For more details on financial information to be provided during the Capital Markets Day, please click [here](#).

The approximately 50 participants in Capital Markets Day 2014 will have the opportunity to learn more about individual businesses and segments, to hear updates on transformational initiatives and to visit the state-of-the-art manufacturing site in Visp for Antibody Drug Conjugates (ADCs).

All other Capital Markets Day presentations are also posted on the [Investor Relations site](#) of [www.lonza.com](http://www.lonza.com).

#### **About Lonza**

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza's stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at [www.lonza.com](http://www.lonza.com).

# Press Release

## Disclaimer

Certain matters discussed in this presentation may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this presentation.

## Lonza Contact Information

Lonza Group Ltd  
Head Investor Relations  
Dirk Oehlers  
Tel +41 61 316 8540  
Fax +41 61 316 9540  
[dirk.oehlers@lonza.com](mailto:dirk.oehlers@lonza.com)

Lonza Group Ltd  
Head Corporate Communications  
Dominik Werner  
Tel +41 61 316 8798  
Fax +41 61 316 9540  
[dominik.werner@lonza.com](mailto:dominik.werner@lonza.com)

Lonza Group Ltd  
Head External Communications  
Constance Ward  
Tel +41 61 316 8840  
Fax +41 61 316 9840  
[constance.ward@lonza.com](mailto:constance.ward@lonza.com)